MedTrace Logo

Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects

NCT02448212 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-02-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the binding of a novel tracer, \[11C\]TASP0410699, using Positron Emission Tomography (PET) scans with or without dosing of TS-121

Conditions

  • Healthy

Interventions

DRUG

TS-121

Oral

DRUG

[11C]TASP0410699

Intravenous radiotracer

RADIATION

Positron Emission Tomography (PET)

Imaging scanning procedure

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Taisho Pharmaceutical R&D Inc.

    lead INDUSTRY

Principal Investigators

  • Richard E. Carson, Ph.D. · Yale University

  • Shoji Yasuda · Taisho Pharmaceutical R&D Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-01-31
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448212 on ClinicalTrials.gov